I believe that this is just while it is part of the SAS program because these patients are helping build the data and proof of efficacy on a drug that is not yet TGA approved for use.
Once approved, I would imaging the special access scheme would be ceased and anyone wanting access would need to pay full freight and possibly seek some form of Medicare reimbursement if available.
What a pain, page-29
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.010(3.77%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $162.7K | 620.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25008 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 34768 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |